Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials
- 18 November 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Clinical Oncology
- Vol. 18 (1), 96-104
- https://doi.org/10.1007/s10147-011-0349-5
Abstract
Ethnic differences in drug susceptibility and toxicity are a major concern, not only in drug development but also in the clinical setting. We review the toxicity profiles of docetaxel according to dose and ethnicity. We analyzed phase II and III clinical trials that included a once-every-3-weeks single-agent docetaxel arm. Logistic regression analysis was applied to identify the significant variables affecting the reported incidence of docetaxel-induced severe neutropenia. Multivariate logistic regression analysis identified studies conducted in Asia [odds ratio (OR) 19.0; 95% confidence interval (95% CI) 3.64-99.0] and docetaxel dose (OR 1.08; 95% CI 1.03-1.13) as independent variables for the incidence of grade 3/4 neutropenia. There is a significant difference in the incidence of docetaxel-induced severe neutropenia between Asian and non-Asian clinical studies. Physicians and pharmacists should consider ethnic diversity in docetaxel toxicity when interpreting the results of clinical trials.Keywords
This publication has 121 references indexed in Scilit:
- Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of ChemotherapyClinical Cancer Research, 2009
- A randomised phase II trial of preoperative chemotherapy of cisplatin–docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG 0204)British Journal of Cancer, 2008
- Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancerBritish Journal of Cancer, 2008
- A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancerZeitschrift für Krebsforschung und Klinische Onkologie, 2007
- Phase II Trial of Docetaxel Therapy in Patients with Advanced Hepatocellular CarcinomaOncology, 2006
- Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trialBritish Journal of Cancer, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinomaEuropean Journal of Cancer, 2000
- Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials groupEuropean Journal of Cancer, 1994
- Activity of docetaxel (Taxotere) in small cell lung cancerEuropean Journal of Cancer, 1994